09 April 2020
The Economist Intelligence Unit (EIU) expects that the global economy will contract by 2.5% in 2020 as a result of the coronavirus pandemic. This represents a much deeper global recession than that experienced during the global financial crisis.
The negative effect on growth will come via both demand and supply channels. Quarantine measures, illness, and negative consumer and business sentiment will suppress demand, with the closure of some factories and disruption to supply chains creating supply bottlenecks.
Some of the key questions discussed in our latest report include:
The Economist Intelligence Unit provides world-leading political and economic analysis and forecasts for 197 countries. Our reports examine and explain the important political and economic trends and developments in each country, providing investors and businesses with key takeaways to understand the current situation and the likely future political and economic developments.
Alongside our comprehensive annual data, we provide quarterly forecasts for 50 countries covering 85% of global output. These forecasts, built using our proprietary econometric models, address the growing need for high-frequency data to help set budgets, investments and economic projections.
The EIU’s quarterly forecasts include up to 51 headline series for G20 countries, the BRICS grouping (comprising Brazil, Russia, India, China, and South Africa), as well as key emerging markets. These forecasts are updated continuously and projected out two years, or eight quarters. Our quarterly-frequency forecasts make use of a pioneering Global Vector Autoregression (GVAR) technique developed by leading econometricians over the past decade. Such models are believed to have strong forecasting properties, particularly in the short run, and to capture cross-quarter and cross-variable dynamics effectively.
Read full report on The Economist web-site
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024